Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassay

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Enzyme immunoassay (EIA) and fluorescence polarization immunoassay (FPIA) methods are commercially available for quantitation of serum amikacin concentration. The purpose of this study was to determine if the two assay methods were comparable and would provide the same estimates for pharmacokinetic parameters and dosage recommendations. A total of 73 amikacin serum samples were used to evaluate the two assay techniques. Forty-four of these samples, obtained from 10 patients, were used to evaluate the comparability of pharmacokinetic parameters and dosage regimens. The correlation coefficient between the two assay methods was 0.98 (y = 1.03jc + 0.64). There were substantial differences in assay performance noted in samples <10 mg/L, 10-20 mg/L, and >20 mg/L, typical concentration ranges for serum sampling used in pharmacokinetic analysis. A difference of ~10% was observed in the determination of amikacin half-life, total body clearance, and dosage calculation. A 7% difference was noted in the volume of distribution. A significant difference (p < 0.05) in volume of distribution and dosage recommendations was noted. Although the two methods for determining amikacin serum concentrations appear to be interchangeable on the basis of the in vitro comparison, significant differences were observed between the two assays in pharmacokinetic parameters and dosage recommendations.

Original languageEnglish (US)
Pages (from-to)48-52
Number of pages5
JournalTherapeutic Drug Monitoring
Volume9
Issue number1
StatePublished - Jan 1 1987

Fingerprint

Fluorescence Polarization Immunoassay
Pharmacokinetics
Amikacin
Immunoenzyme Techniques
Assays
Fluorescence
Polarization
Enzymes
Serum
Half-Life
Sampling

Keywords

  • Amikacin
  • Assay comparison
  • Enzyme immunoassay
  • Fluorescence polarization immunoassay

Cite this

@article{7e8b6ff367e3467691a46f167677d89a,
title = "Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassay",
abstract = "Enzyme immunoassay (EIA) and fluorescence polarization immunoassay (FPIA) methods are commercially available for quantitation of serum amikacin concentration. The purpose of this study was to determine if the two assay methods were comparable and would provide the same estimates for pharmacokinetic parameters and dosage recommendations. A total of 73 amikacin serum samples were used to evaluate the two assay techniques. Forty-four of these samples, obtained from 10 patients, were used to evaluate the comparability of pharmacokinetic parameters and dosage regimens. The correlation coefficient between the two assay methods was 0.98 (y = 1.03jc + 0.64). There were substantial differences in assay performance noted in samples <10 mg/L, 10-20 mg/L, and >20 mg/L, typical concentration ranges for serum sampling used in pharmacokinetic analysis. A difference of ~10{\%} was observed in the determination of amikacin half-life, total body clearance, and dosage calculation. A 7{\%} difference was noted in the volume of distribution. A significant difference (p < 0.05) in volume of distribution and dosage recommendations was noted. Although the two methods for determining amikacin serum concentrations appear to be interchangeable on the basis of the in vitro comparison, significant differences were observed between the two assays in pharmacokinetic parameters and dosage recommendations.",
keywords = "Amikacin, Assay comparison, Enzyme immunoassay, Fluorescence polarization immunoassay",
author = "Bleske, {Barry E.} and Larson, {Tom A} and Rotschafer, {John C}",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "48--52",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassay

AU - Bleske, Barry E.

AU - Larson, Tom A

AU - Rotschafer, John C

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Enzyme immunoassay (EIA) and fluorescence polarization immunoassay (FPIA) methods are commercially available for quantitation of serum amikacin concentration. The purpose of this study was to determine if the two assay methods were comparable and would provide the same estimates for pharmacokinetic parameters and dosage recommendations. A total of 73 amikacin serum samples were used to evaluate the two assay techniques. Forty-four of these samples, obtained from 10 patients, were used to evaluate the comparability of pharmacokinetic parameters and dosage regimens. The correlation coefficient between the two assay methods was 0.98 (y = 1.03jc + 0.64). There were substantial differences in assay performance noted in samples <10 mg/L, 10-20 mg/L, and >20 mg/L, typical concentration ranges for serum sampling used in pharmacokinetic analysis. A difference of ~10% was observed in the determination of amikacin half-life, total body clearance, and dosage calculation. A 7% difference was noted in the volume of distribution. A significant difference (p < 0.05) in volume of distribution and dosage recommendations was noted. Although the two methods for determining amikacin serum concentrations appear to be interchangeable on the basis of the in vitro comparison, significant differences were observed between the two assays in pharmacokinetic parameters and dosage recommendations.

AB - Enzyme immunoassay (EIA) and fluorescence polarization immunoassay (FPIA) methods are commercially available for quantitation of serum amikacin concentration. The purpose of this study was to determine if the two assay methods were comparable and would provide the same estimates for pharmacokinetic parameters and dosage recommendations. A total of 73 amikacin serum samples were used to evaluate the two assay techniques. Forty-four of these samples, obtained from 10 patients, were used to evaluate the comparability of pharmacokinetic parameters and dosage regimens. The correlation coefficient between the two assay methods was 0.98 (y = 1.03jc + 0.64). There were substantial differences in assay performance noted in samples <10 mg/L, 10-20 mg/L, and >20 mg/L, typical concentration ranges for serum sampling used in pharmacokinetic analysis. A difference of ~10% was observed in the determination of amikacin half-life, total body clearance, and dosage calculation. A 7% difference was noted in the volume of distribution. A significant difference (p < 0.05) in volume of distribution and dosage recommendations was noted. Although the two methods for determining amikacin serum concentrations appear to be interchangeable on the basis of the in vitro comparison, significant differences were observed between the two assays in pharmacokinetic parameters and dosage recommendations.

KW - Amikacin

KW - Assay comparison

KW - Enzyme immunoassay

KW - Fluorescence polarization immunoassay

UR - http://www.scopus.com/inward/record.url?scp=0023154665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023154665&partnerID=8YFLogxK

M3 - Article

C2 - 3554628

AN - SCOPUS:0023154665

VL - 9

SP - 48

EP - 52

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -